Maarten van den Boer

Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants

Maarten Timmers, Paulien Ravenstijn, Liwen Xi et al. · Journal of Psychopharmacology · 2018 · 63 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +12

Fatty Acid Amide Hydrolase Inhibition by JNJ‐42165279: A Multiple‐Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers

Andrey Postnov, Mark E. Schmidt, Darrel J. Pemberton et al. · Clinical and Translational Science · 2018 · 48 citations · Full text

Medicine, Neuroscience, Pharmacology +11

The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis

Ivo Nnane, Bart Frederick, Zhenling Yao et al. · British Journal of Clinical Pharmacology · 2020 · 36 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Joris Vandenbossche, Wolfgang Jessner, Maarten van den Boer et al. · Advances in Therapy · 2019 · 28 citations

Pharmacy, Pharmacokinetics, Pharmacology +11